TurtleTree, a San Francisco CA-based biotech company which leverages cell-based technology for milk production, raised US$30M in Series A funding.
The round was led by Verso Capital.
The company intends to use the funds to continue expanding its portfolio of food items and technology development efforts, as well as to grow its R&D team.
Led by CEO Fengru Lin and Chief Strategy Officer Max Rye, TurtleTree is a biotech company dedicated to producing a new generation of milk ingredients, which offer proven benefits for immune system function, gut health, and cognitive development, utilizing proprietary, cell-based technology.
The company plans to scale up its research and production efforts to launch lactoferrin, a bioactive protein, as its first commercial product.